EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI‐Treated Acute Myocardial Infarction: A Meta‐Analysis of Clinical Efficacy and Safety

Tang Tang iD, Huimin Yu iD, Yun Zhang iD, Shuang Li iD, Mu Guo iD

Cardiology Research and Practice · 2026-01 · 2026 (1)

DOI: 10.1155/crp/1274068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiology Research and Practice, online erschienen am 16.07.2026. Verfasst von Tang Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated Tongji University, Shanghai, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tongji University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To systematically review the efficacy and safety of dapagliflozin and sacubitril/valsartan (SV) in patients with heart failure (HF) following percutaneous coronary intervention (PCI)–treated acute myocardial infarction (AMI) and to provide evidence for clinical practice.

Methods

Seven electronic databases were systematically searched from their inception to July 25, 2024. Following literature screening, data extraction, and risk of bias assessment, 14 randomized controlled trials involving 1310 patients were included. A meta‐analysis was subsequently conducted using RevMan 5.4 and Stata 18.

Results

Meta‐analysis results showed that dapagliflozin combined with SV was superior to the control in improving left ventricular ejection fraction (LVEF) (WMD = 3.79, 95% CI: 2.70∼4.87; p < 0.001) and reducing N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels (WMD = −83.49, 95% CI: −129.33∼−37.65; p = 0.0004). This combination also significantly reduced left ventricular end‐diastolic diameter (LVEDD) (WMD = −2.27, 95% CI: −3.64∼−0.90; p = 0.001), left ventricular end‐systolic diameter (LVESD) (WMD = −3.29, 95% CI: −3.98∼−2.59; p < 0.001), left ventricular remodeling index (LVRI) (WMD = −0.08, 95% CI: −0.10∼−0.06; p < 0.001), and left ventricular mass index (LVMI) (WMD = −8.84, 95% CI: −12.25∼−5.43; p < 0.001), while increasing the 6‐min walking distance (6MWD) (WMD = 51.74, 95% CI: 32.33∼71.14; p < 0.001). Compared with SV monotherapy, adding dapagliflozin reduced major adverse cardiovascular event (MACE) incidence (OR = 0.24, 95% CI: 0.15∼0.39; p < 0.001). However, no significant difference in adverse drug events (ADEs) was observed. Subgroup analyses revealed no significant differences in NT‐proBNP (WMD = −194.85, 95% CI: −396.53∼6.82; p = 0.06), LVEDD (WMD = −1.50, 95% CI: −3.90∼0.89; p = 0.22), or the incidence of ADE (OR = 1.26, 95% CI: 0.74∼2.14; p = 0.39) when the follow‐up duration was short (≤ 12 w). Additionally, significant heterogeneity was observed across studies for most outcomes. However, this heterogeneity was markedly reduced in the long‐term follow‐up subgroup (≥ 24 w), and the results were consistent with those of previous meta‐analyses.

Conclusion

Current evidence suggests that early initiation of dapagliflozin combined with SV offers superior efficacy and cardiovascular benefits for patients with HF following PCI‐treated AMI. These benefits become increasingly evident with sustained treatment. Nevertheless, these conclusions warrant validation through more high‐quality evidence.

Schlagwörter

Stichwörter der Autor:innen

dapagliflozinheart failuremeta-analysismyocardial infarctionsacubitril/valsartan

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated Tongji University, Shanghai, China.
  • Department of Clinical Pharmacy, General Hospital of Eastern Theater Command, Nanjing, China.
  • Department of Cardiology, Shanghai Fourth People's Hospital Affiliated Tongji University, Shanghai, China.

ORCID-Profile: Tang Tang, Huimin Yu, Yun Zhang, Shuang Li, Mu Guo

Förderung

  • Tongji University

Zitieren

APA

Tang, T., Yu, H., Zhang, Y., Li, S., & Guo, M. (2026). Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI‐Treated Acute Myocardial Infarction: A Meta‐Analysis of Clinical Efficacy and Safety. Cardiology Research and Practice, 2026(1). https://doi.org/10.1155/crp/1274068

Vancouver

Tang T, Yu H, Zhang Y, Li S, Guo M. Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI‐Treated Acute Myocardial Infarction: A Meta‐Analysis of Clinical Efficacy and Safety. Cardiology Research and Practice. 2026;2026(1). doi:10.1155/crp/1274068

BibTeX
@article{Tang2026,
  author = {Tang, Tang and Yu, Huimin and Zhang, Yun and Li, Shuang and Guo, Mu},
  title = {Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI‐Treated Acute Myocardial Infarction: A Meta‐Analysis of Clinical Efficacy and Safety},
  journal = {Cardiology Research and Practice},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crp/1274068}
}
Kostenlos starten →